Literature DB >> 20056635

Marginal and mixed-effects models in the analysis of human papillomavirus natural history data.

Xiaonan Xue1, Stephen J Gange, Ye Zhong, Robert D Burk, Howard Minkoff, L Stewart Massad, D Heather Watts, Mark H Kuniholm, Kathryn Anastos, Alexandra M Levine, Melissa Fazzari, Gypsyamber D'Souza, Michael Plankey, Joel M Palefsky, Howard D Strickler.   

Abstract

Human papillomavirus (HPV) natural history has several characteristics that, at least from a statistical perspective, are not often encountered elsewhere in infectious disease and cancer research. There are, for example, multiple HPV types, and infection by each HPV type may be considered separate events. Although concurrent infections are common, the prevalence, incidence, and duration/persistence of each individual HPV can be separately measured. However, repeated measures involving the same subject tend to be correlated. The probability of detecting any given HPV type, for example, is greater among individuals who are currently positive for at least one other HPV type. Serial testing for HPV over time represents a second form of repeated measures. Statistical inferences that fail to take these correlations into account would be invalid. However, methods that do not use all the data would be inefficient. Marginal and mixed-effects models can address these issues but are not frequently used in HPV research. The current study provides an overview of these methods and then uses HPV data from a cohort of HIV-positive women to illustrate how they may be applied, and compare their results. The findings show the greater efficiency of these models compared with standard logistic regression and Cox models. Because mixed-effects models estimate subject-specific associations, they sometimes gave much higher effect estimates than marginal models, which estimate population-averaged associations. Overall, the results show that marginal and mixed-effects models are efficient for studying HPV natural history, but also highlight the importance of understanding how these models differ.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20056635      PMCID: PMC2839537          DOI: 10.1158/1055-9965.EPI-09-0546

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  16 in total

1.  Sample size and power calculations with correlated binary data.

Authors:  W Pan
Journal:  Control Clin Trials       Date:  2001-06

2.  Design and sample size estimation in clinical trials with clustered survival times as the primary endpoint.

Authors:  Tailiang Xie; Joel Waksman
Journal:  Stat Med       Date:  2003-09-30       Impact factor: 2.373

3.  Analysis of data with multiple sources of correlation in the framework of generalized estimating equations.

Authors:  Justine Shults; Melicia C Whitt; Shiriki Kumanyika
Journal:  Stat Med       Date:  2004-10-30       Impact factor: 2.373

4.  Comparison of population-averaged and subject-specific approaches for analyzing repeated binary outcomes.

Authors:  F B Hu; J Goldberg; D Hedeker; B R Flay; M A Pentz
Journal:  Am J Epidemiol       Date:  1998-04-01       Impact factor: 4.897

5.  Binomial regression in GLIM: estimating risk ratios and risk differences.

Authors:  S Wacholder
Journal:  Am J Epidemiol       Date:  1986-01       Impact factor: 4.897

6.  Design and analysis considerations in a cohort study involving repeated measurement of both exposure and outcome: the association between genital papillomavirus infection and risk of cervical intraepithelial neoplasia.

Authors:  S W Duffy; T E Rohan; J R McLaughlin
Journal:  Stat Med       Date:  1994-02-28       Impact factor: 2.373

7.  Natural history of cervicovaginal papillomavirus infection in young women.

Authors:  G Y Ho; R Bierman; L Beardsley; C J Chang; R D Burk
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

8.  The Women's Interagency HIV Study. WIHS Collaborative Study Group.

Authors:  S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman
Journal:  Epidemiology       Date:  1998-03       Impact factor: 4.822

9.  Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women.

Authors:  Howard D Strickler; Joel M Palefsky; Keerti V Shah; Kathryn Anastos; Robert S Klein; Howard Minkoff; Ann Duerr; L Stewart Massad; David D Celentano; Charles Hall; Melissa Fazzari; Susan Cu-Uvin; Melanie Bacon; Paula Schuman; Alexandra M Levine; Amanda J Durante; Stephen Gange; Sandra Melnick; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2003-07-16       Impact factor: 13.506

Review 10.  A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.

Authors:  David Jenkins
Journal:  Gynecol Oncol       Date:  2008-07-23       Impact factor: 5.482

View more
  55 in total

1.  Sexual transmission of oral human papillomavirus infection among men.

Authors:  Kristina R Dahlstrom; Ann N Burchell; Agnihotram V Ramanakumar; Allita Rodrigues; Pierre-Paul Tellier; James Hanley; François Coutlée; Eduardo L Franco
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11-12       Impact factor: 4.254

2.  Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection.

Authors:  L Stewart Massad; Xianhong Xie; Teresa Darragh; Howard Minkoff; Alexandra M Levine; D Heather Watts; Rodney L Wright; Gypsyamber D'Souza; Christine Colie; Howard D Strickler
Journal:  Obstet Gynecol       Date:  2011-10       Impact factor: 7.661

3.  The Natural History of Oral Human Papillomavirus in Young Costa Rican Women.

Authors:  Daniel C Beachler; Krystle A Lang Kuhs; Linda Struijk; John Schussler; Rolando Herrero; Carolina Porras; Allan Hildesheim; Bernal Cortes; Joshua Sampson; Wim Quint; Paula Gonzalez; Aimée R Kreimer
Journal:  Sex Transm Dis       Date:  2017-07       Impact factor: 2.830

4.  Risk of Delayed Human Papillomavirus Vaccination in Inner-City Adolescent Women.

Authors:  Nicolas F Schlecht; Angela Diaz; Viswanathan Shankar; Arnold H Szporn; Maoxin Wu; Anne Nucci-Sack; Ken Peake; Howard D Strickler; Robert D Burk
Journal:  J Infect Dis       Date:  2016-10-12       Impact factor: 5.226

5.  A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.

Authors:  Barbara J Mason; Rebecca Crean; Vivian Goodell; John M Light; Susan Quello; Farhad Shadan; Kimberly Buffkins; Mark Kyle; Murali Adusumalli; Adnan Begovic; Santosh Rao
Journal:  Neuropsychopharmacology       Date:  2012-02-29       Impact factor: 7.853

6.  Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults.

Authors:  Daniel C Beachler; Elizabeth A Sugar; Joseph B Margolick; Kathleen M Weber; Howard D Strickler; Dorothy J Wiley; Ross D Cranston; Robert D Burk; Howard Minkoff; Susheel Reddy; Weihong Xiao; Yingshi Guo; Maura L Gillison; Gypsyamber D'Souza
Journal:  Am J Epidemiol       Date:  2014-12-04       Impact factor: 4.897

7.  The Cervicovaginal Microbiota and Its Associations With Human Papillomavirus Detection in HIV-Infected and HIV-Uninfected Women.

Authors:  Laura L Reimers; Supriya D Mehta; L Stewart Massad; Robert D Burk; Xianhong Xie; Jacques Ravel; Mardge H Cohen; Joel M Palefsky; Kathleen M Weber; Xiaonan Xue; Kathryn Anastos; Howard Minkoff; Jessica Atrio; Gypsyamber D'Souza; Qian Ye; Christine Colie; Christine P Zolnik; Gregory T Spear; Howard D Strickler
Journal:  J Infect Dis       Date:  2016-08-11       Impact factor: 5.226

8.  Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer.

Authors:  S L Sudenga; S Shrestha
Journal:  Int J Infect Dis       Date:  2013-02-27       Impact factor: 3.623

9.  Retention among North American HIV-infected persons in clinical care, 2000-2008.

Authors:  Peter Rebeiro; Keri N Althoff; Kate Buchacz; John Gill; Michael Horberg; Hartmut Krentz; Richard Moore; Timothy R Sterling; John T Brooks; Kelly A Gebo; Robert Hogg; Marina Klein; Jeffrey Martin; Michael Mugavero; Sean Rourke; Michael J Silverberg; Jennifer Thorne; Stephen J Gange
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

10.  Natural history of anal vs oral HPV infection in HIV-infected men and women.

Authors:  Daniel C Beachler; Gypsyamber D'Souza; Elizabeth A Sugar; Wiehong Xiao; Maura L Gillison
Journal:  J Infect Dis       Date:  2013-04-17       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.